BI-1569912

N/A

Report date: 2026/03/23 20:03:44
NME

Base Information

Drug NameBI-1569912
Drug Alias NameBI-1569912
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionGlutamate [NMDA] receptor subunit epsilon 2 modulators
TargetsGlutamate [NMDA] receptor subunit epsilon 2
Therapy Area/IndicationsDepressive Disorder, MajorDepressive Disorder
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumBulgaria +[8] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesBoehringer Ingelheim International Gmbh
China Registration ClassN/A

Develop Information

Active CompaniesC.H. Boehringer Sohn Ag & Co. KgBoehringer Ingelheim International GmbhBoehringer Ingelheim (China) Investment Co Ltd
Inactive CompaniesN/A
Active IndicationsDepressive Disorder, MajorDepressive Disorder
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A